Altria Group reported 2025 adjusted diluted EPS of $5.42, up 4.4% year over year, as the company highlighted momentum in its smoke-free portfolio and $8 billion in total shareholder returns through dividends and share repurchases. Full-year net revenues declined 3.1% to $23.3 billion, while revenues net of excise taxes fell 1.5% to $20.1 billion. In the fourth quarter, Altria repurchased $288 million in stock and paid $1.8 billion in dividends. The company also noted recent FDA marketing authorizations for additional on! PLUS nicotine pouch variants and continued progress under its multi-year Optimize & Accelerate cost-savings initiative.
Altria expects 2026 adjusted diluted EPS in a range of $5.56 to $5.72, representing projected growth of 2.5% to 5.5%. Guidance assumes continued investment in smoke-free products, limited enforcement impact from illicit e-vapor products, and that NJOY ACE will not return to the market in 2026. The company reaffirmed its long-term strategy of building an FDA-authorized smoke-free portfolio while maintaining leadership in traditional tobacco, targeting mid-single-digit earnings and dividend growth through 2028.
